MARKET

NBSE

NBSE

NeuBase Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.750
-0.170
-4.34%
Opening 10:40 09/20 EDT
OPEN
3.800
PREV CLOSE
3.920
HIGH
3.930
LOW
3.750
VOLUME
29.81K
TURNOVER
--
52 WEEK HIGH
12.89
52 WEEK LOW
3.260
MARKET CAP
122.69M
P/E (TTM)
-4.1455
1D
5D
1M
3M
1Y
5Y
NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome(TM) to address disease at the base level using a new class of precision genetic medicines, announced today that Dietrich A. Stephan...
GlobeNewswire · 4d ago
NeuBase to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
PITTSBURGH, Sept. 15, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicin...
GlobeNewswire · 4d ago
NeuBase Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investment Conference
PITTSBURGH, Sept. 01, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicin...
GlobeNewswire · 09/01 20:05
What Type Of Shareholders Make Up NeuBase Therapeutics, Inc.'s (NASDAQ:NBSE) Share Registry?
If you want to know who really controls NeuBase Therapeutics, Inc. ( NASDAQ:NBSE ), then you'll have to look at the...
Simply Wall St. · 08/31 12:45
BRIEF-NeuBase Therapeutics Inc Entered Into An Open Market Sale Agreement With Jefferies Llc
reuters.com · 08/27 22:15
Sio Capital Management, LLC Buys Aveanna Healthcare Holdings Inc, Amgen Inc, Integer Holdings ...
GuruFocus News · 08/24 15:38
--RBC Trims Price Target on NeuBase Therapeutics to $15 From $16 to Reflect Operating Expenses; Outperform, Speculative Risk Kept
MT Newswires · 08/16 09:07
BRIEF-Neubase Therapeutics Reports Financial Results For The Third Quarter Of Fiscal Year 2021 And Recent Operating Highlights
reuters.com · 08/12 20:46
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NBSE. Analyze the recent business situations of NeuBase Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NBSE stock price target is 16.25 with a high estimate of 18.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 75
Institutional Holdings: 10.44M
% Owned: 31.91%
Shares Outstanding: 32.72M
TypeInstitutionsShares
Increased
16
2.68M
New
15
1.76M
Decreased
18
1.47M
Sold Out
13
362.91K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.30%
Pharmaceuticals & Medical Research
-0.38%
Key Executives
President/Chief Executive Officer/Director
Dietrich Stephan
Chief Financial Officer/Treasurer/Secretary
Sam Backenroth
Chief Operating Officer
William Mann
Chief Scientific Officer
Curt Bradshaw
Other
Kianoush Motesharei
Other
Sandra Rojas-Caro
Director
Gerald McDougall
Independent Director
Dov Goldstein
Independent Director
Franklyn Prendergast
Independent Director
Eric Richman
No Data
  • All
  • Financials
  • Insiders
More
About NBSE
NeuBase Therapeutics, Inc. is a pre-clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.

Webull offers kinds of Neubase Therapeutics Inc stock information, including NASDAQ:NBSE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBSE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBSE stock methods without spending real money on the virtual paper trading platform.